Research status and future prospects of latent tuberculosis infection from a bibliometric perspective

doi:10.19982/j.issn.1000-6621.20240235

Abstract

Abstract:

Objective: This study employs bibliometric analysis to examine the literature on latent tuberculosis infection (LTBI), with the goal of providing researchers with a comprehensive understanding of the current research landscape and future trends. Methods: The analysis was conducted using the expanded version of the Science Citation Index in the Web of Science Core Collection database, with the search field set to the topic. The primary keywords included ‘Latent Tuberculosis’ ‘Latent TB’ and ‘LTBI’. The literature search was conducted on May 13, 2024, and the publication period was restricted to 2014—2023. Only original research articles and review papers published in English were included, resulting in a total of 4210 relevant publications. VOSviewer software was employed to visualize the data and perform an in-depth analysis of the LTBI research field, focusing on publication trends, journal analysis, highly cited papers, international research collaboration networks, and keyword clustering. Results: Since the World Health Organization introduced its LTBI strategy in 2015, the topic has garnered sustained attention from the global academic community. From January 2014 to December 2024, we identified 4210 relevant articles, which collectively received 74324 citations, averaging 17.65 citations per article. The United States led in the number of publications (1314 articles, 31.21%), followed by China (587 articles, 13.94%). Analysis of international research cooperation networks revealed that latent tuberculosis infection research is marked by close collaboration among countries and regions, with the United States, China, the United Kingdom, India, and Italy taking leading roles. Keyword clustering indicated that the primary research focuses in this field currently include immunological mechanisms, comprehensive management, LTBI in the context of rheumatic diseases, and LTBI screening. Conclusion: This study highlights the current research landscape and future trends in the field of LTBI, offering valuable insights and references for research institutions and scholars.

Key words: Mycobacterium tuberculosis, Infection, Bibliometrics, Review literature

CLC Number:

Yang Yixuan, Xin Jibin, Ruan Qiaoling, Ying Jun, Zhang Wenhong. Research status and future prospects of latent tuberculosis infection from a bibliometric perspective[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1209-1218. doi: 10.19982/j.issn.1000-6621.20240235

Figures/Tables 7

References 58

[1]	Cohen A, Mathiasen VD, Schön T, et al. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2019, 54(3):1900655. doi:10.1183/13993003.00655-2019.
[2]	Drain PK, Bajema KL, Dowdy D, et al. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev, 2018, 31(4): e00021-18. doi:10.1128/CMR.00021-18.
[3]	Furin J, Cox H, Pai M. Tuberculosis. Lancet, 2019, 393(10181):1642-1656. doi:10.1016/S0140-6736(19)30308-3. pmid: 30904262
[4]	Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med, 2021, 385(24):2271-2280. doi:10.1056/NEJMcp2108501.
[5]	World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. Geneva: World Health Organization, 2015.
[6]	Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol, 2022, 20(12):750-766. doi:10.1038/s41579-022-00763-4.
[7]	阮巧玲, 黄希田, 刘雪峰, 等. 免疫受损人群的潜伏性结核感染筛查和预防性治疗. 中国防痨杂志, 2017, 39(7):765-769. doi:10.3969/j.issn.1000-6621.2017.07.020.
[8]	何张玙璠, 周晶雨, 周哲, 等. 新型生物标志物组合在鉴别活动性结核与结核潜伏感染中的应用. 中华传染病杂志, 2023, 41(6):407-411. doi:10.3760/cma.j.cn311365-20221019-00438.
[9]	中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识. 中国防痨杂志, 2021, 43(9):874-878. doi:10.3969/j.issn.1000-6621.2021.09.004.
[10]	杨清銮, 阮巧玲, 张文宏. HIV感染人群结核分枝杆菌潜伏感染筛查与预防性治疗. 临床内科杂志, 2019, 36(11):729-732. doi:10.3969/j.issn.1001-9057.2019.11.004.
[11]	Pu QH, Lyu QJ, Su HY. Bibliometric analysis of scientific publications in transplantation journals from Mainland China, Japan, South Korea and Taiwan between 2006 and 2015. BMJ Open,2016, 6(8):e011623. doi:10.1136/bmjopen-2016-011623.
[12]	van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, 2010, 84(2):523-538. doi:10.1007/s11192-009-0146-3. pmid: 20585380
[13]	刘雪立. 基于Web of Science和ESI数据库高被引论文的界定方法. 中国科技期刊研究, 2012, 23(6):975-978. doi:10.3969/j.issn.1001-7143.2012.06.015.
[14]	Esaulova E, Das S, Singh DK, et al. The immune landscape in tuberculosis reveals populations linked to disease and latency. Cell Host Microbe, 2021, 29(2):165-178. doi:10.1016/j.chom.2020.11.013. pmid: 33340449
[15]	Khader SA, Divangahi M, Hanekom W, et al. Targeting innate immunity for tuberculosis vaccination. J Clin Invest, 2019, 129(9):3482-3491. doi:10.1172/JCI128877. pmid: 31478909
[16]	Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis, 2021, 21(3):354-365. doi:10.1016/S1473-3099(20)30914-2. pmid: 33508224
[17]	Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi:10.1056/NEJMoa1806808.
[18]	Ryckman T, Weiser J, Gombe M, et al. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis. Lancet Glob Health, 2023, 11(8):e1205 -e1216. doi:10.1016/S2214-109X(23)00251-6.
[19]	Velen K, Shingde RV, Ho J, et al. The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis. Eur Respir J, 2021, 58(6):2100266. doi:10.1183/13993003.00266-2021.
[20]	Roca FJ, Whitworth LJ, Redmond S, et al. TNF Induces Pathogenic Programmed Macrophage Necrosis in Tuberculosis through a Mitochondrial-Lysosomal-Endoplasmic Reticulum Circuit. Cell, 2019, 178(6):1344-1361. doi:10.1016/j.cell.2019.08.004. pmid: 31474371
[21]	Roca FJ, Whitworth LJ, Prag HA, et al. Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport. Science, 2022, 376(6600):eabh2841. doi:10.1126/science.abh2841.
[22]	Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484.
[23]	Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E, et al. Diagnosis for Latent Tuberculosis Infection: New Alternatives. Front Immunol, 2020, 11:2006. doi:10.3389/fimmu.2020.02006. pmid: 33013856
[24]	Zhou G, Luo Q, Luo S, et al. Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis, 2020, 20(12):1457-1469. doi:10.1016/S1473-3099(20)30276-0. pmid: 32673595
[25]	Hamada Y, Cirillo DM, Matteelli A, et al. Tests for tuberculosis infection: landscape analysis. Eur Respir J, 2021, 58(5):2100167. doi:10.1183/13993003.00167-2021.
[26]	Menzies D, Adjobimey M, Ruslami R, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med, 2018, 379(5):440-453. doi:10.1056/NEJMoa1714283.
[27]	Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019, 381(25):2429-2439. doi:10.1056/NEJMoa1909953.
[28]	Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M.tuberculosis Infection with H4:IC 31 Vaccine or BCG Revaccination. N Engl J Med, 2018, 379(2):138-149. doi:10.1056/NEJMoa1714021.
[29]	Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med, 2015, 372(22):2127-2135. doi:10.1056/NEJMra1405427.
[30]	Alsdurf H, Hill PC, Matteelli A, et al. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis, 2016, 16(11):1269-1278. doi:10.1016/S1473-3099(16)30216-X. pmid: 27522233
[31]	Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev, 2014, 27(1):3-20. doi:10.1128/CMR.00034-13.
[32]	Koeken V, Verrall AJ, Netea MG, et al. Trained innate immunity and resistance to Mycobacterium tuberculosis infection. Clin Microbiol Infect, 2019, 25(12):1468-1472. doi:10.1016/j.cmi.2019.02.015.
[33]	Ferluga J, Yasmin H, Al-Ahdal MN, et al. Natural and trained innate immunity against Mycobacterium tuberculosis. Immunobiology, 2020, 225(3):151951. doi:10.1016/j.imbio.2020.151951.
[34]	Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis Infections. Microbiol Spectr, 2019, 7(4): 10.1128/microbiolspec.gpp3-0022-2018. doi:10.1128/microbiolspec.GPP3-0022-2018.
[35]	Chai Q, Wang L, Liu CH, et al. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cell Mol Immunol, 2020, 17(9):901-913. doi:10.1038/s41423-020-0502-z.
[36]	Gideon HP, Hughes TK, Tzouanas CN, et al. Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control. Immunity, 2022, 55(5):827-846. doi:10.1016/j.immuni.2022.04.004. pmid: 35483355
[37]	Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, 2016, 387(10035):2312-2322. doi:10.1016/S0140-6736(15)01316-1. pmid: 27017310
[38]	Roy Chowdhury R, Vallania F, Yang Q, et al. A multi-cohort study of the immune factors associated with M.tuberculosis infection outcomes. Nature, 2018, 560(7720):644-648. doi:10.1038/s41586-018-0439-x.
[39]	Scriba TJ, Netea MG, Ginsberg AM. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Semin Immunol, 2020, 50:101431. doi:10.1016/j.smim.2020.101431.
[40]	Rangaka MX, Frick M, Churchyard G, et al. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment. Lancet Respir Med, 2023, 11(4):380-390. doi:10.1016/S2213-2600(23)00084-X. pmid: 36966794
[41]	Laghari M, Sulaiman S, Khan AH, et al. Contact screening and risk factors for TB among the household contact of children with active TB: a way to find source case and new TB cases. BMC Public Health, 2019, 19(1):1274. doi:10.1186/s12889-019-7597-0. pmid: 31533689
[42]	Li M, Guo M, Peng Y, et al. High proportion of tuberculosis transmission among social contacts in rural China: a 12-year prospective population-based genomic epidemiological study. Emerg Microbes Infect, 2022, 11(1):2102-2111. doi:10.1080/22221751.2022.2112912.
[43]	Chandrashekara S, Panchagnula R, Chennupati Y. Prevalence of LTBI in patients with autoimmune diseases and accuracy of IGRA in predicting TB relapse. Rheumatology (Oxford), 2023, 62(12):3952-3956. doi:10.1093/rheumatology/kead315.
[44]	Vanvalkenburg A, Kaipilyawar V, Sarkar S, et al. Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis. Front Immunol, 2022, 13:1011166. doi:10.3389/fimmu.2022.1011166.
[45]	Bhargava A, Bhargava M, Meher A, et al. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. Lancet, 2023, 402(10402):627-640. doi:10.1016/S0140-6736(23)01231-X. pmid: 37567200
[46]	Shafeque A, Bigio J, Hogan CA, et al. Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?. J Clin Microbiol, 2020, 58(9): e01950-19. doi:10.1128/JCM.01950-19.
[47]	Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Microbiol Spectr, 2017, 5(1). doi:10.1128/microbiolspec.TNMI7-0028-2016.
[48]	Soler-Garcia A, Gamell A, Pérez-Porcuna T, et al. Performance of QuantiFERON-TB Gold Plus assays in children and adolescents at risk of tuberculosis: a cross-sectional multicentre study. Thorax, 2022, 77(12):1193-1201. doi:10.1136/thoraxjnl-2021-217592.
[49]	Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020, 577(7788):95-102. doi:10.1038/s41586-019-1817-8.
[50]	Sudbury EL, Clifford V, Messina NL, et al. Mycobacterium tuberculosis-specific cytokine biomarkers to differentiate active TB and LTBI: A systematic review. J Infect, 2020, 81(6):873-881. doi:10.1016/j.jinf.2020.09.032. pmid: 33007340
[51]	Gong W, Wu X. Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy. Front Microbiol, 2021, 12:745592. doi:10.3389/fmicb.2021.745592.
[52]	World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[53]	Bonnet M, Vasiliu A, Tchounga BK, et al. Effectiveness of a community-based approach for the investigation and management of children with household tuberculosis contact in Cameroon and Uganda: a cluster-randomised trial. Lancet Glob Health, 2023, 11(12): e 1911-e1921. doi:10.1016/S2214-109X(23)00430-8.
[54]	Fox GJ, Nhung NV, Sy DN, et al. Household-Contact Investigation for Detection of Tuberculosis in Vietnam. N Engl J Med, 2018, 378(3):221-229. doi:10.1056/NEJMoa1700209.
[55]	Goletti D, Petrone L, Ippolito G, et al. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther, 2018, 16(6):501-512. doi:10.1080/14787210.2018.1483238. pmid: 29848120
[56]	Meije Y, Piersimoni C, Torre-Cisneros J, et al. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect, 2014, 20 Suppl 7: 89-101. doi:10.1111/1469-0691.12641.
[57]	Vasiliu A, Martinez L, Gupta RK, et al. Tuberculosis prevention: current strategies and future directions. Clin Microbiol Infect, 2023, 30(9):1123-1130. doi:10.1016/j.cmi.2023.10.023.
[58]	Harries AD, Kumar AMV, Satyanarayana S, et al. Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up. Expert Rev Respir Med, 2020, 14(2):195-208. doi:10.1080/17476348.2020.1694907.

排名	期刊	发文量(篇)	被引次数	2022年影响因子	2022年JCR分区
1	PLOS ONE	246	3749	3.7	Q2
2	INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE	161	2106	4.0	Q2
3	FRONTIERS IN IMMUNOLOGY	126	1670	7.1	Q1
4	BMC INFECTIOUS DISEASES	117	1656	3.7	Q3
5	TUBERCULOSIS	102	1874	3.2	Q3
6	CLINICAL INFECTIOUS DISEASES	91	2454	11.8	Q1
7	SCIENTIFIC REPORTS	78	864	4.6	Q2
8	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	67	1002	8.4	Q1
9	JOURNAL OF INFECTIOUS	53	1431	28.2	Q1
10	FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY	45	295	5.7	Q1

排名	期刊	被引次数	发文量(篇)	2022年影响因子	2022年JCR分区
1	PLOS ONE	3749	246	3.7	Q2
2	CLINICAL INFECTIOUS DISEASES	2454	91	11.8	Q1
3	EUROPEAN RESPIRATORY JOURNAL	2406	40	24.9	Q1
4	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	2106	161	8.4	Q1
5	LANCET INFECTIOUS DISEASES	1997	24	56.3	Q1
6	TUBERCULOSIS	1874	102	3.2	Q3
7	FRONTIERS IN IMMUNOLOGY	1670	126	7.1	Q1
8	BMC INFECTIOUS DISEASES	1656	117	3.7	Q3
9	JOURNAL OF INFECTION	1431	53	28.2	Q1
10	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE	1414	32	24.7	Q1

排名	题目	通信作者	机构/国别	年份	期刊	被引次数	文章类型
1	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection	Pai, M	McGill Univ/ Canada	2014	CLINICAL MICROBIO-LOGY REVIEWS	568	综述
2	Latent Mycobacterium tuberculosis Infection	Getahun, H	WHO/ Switzerland	2015	THE NEW ENGLAND JOURNAL OF MEDICINE	485	综述
3	Prevention of M-tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination	Hatherill, M	Univ Cape Town/South Africa	2018	THE NEW ENGLAND JOURNAL OF MEDICINE	431	论著
4	The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis	Menzies, D	Montreal Chest Inst/ Canada	2016	LANCET INFECTIOUS DISEASES	307	综述
5	The global prevalence of latent tuberculosis: a systematic review and meta-analysis	Wejse, C	Aarhus Univ Hosp/Denmark	2019	EUROPEAN RESPIRATORY JOURNAL	264	综述
6	Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis	Van Der Meeren, O	Glaxo Smith Kline/Belgium	2019	THE NEW ENGLAND JOURNAL OF MEDICINE	263	论著
7	Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults	Menzies, D	Montreal Chest Inst/Canada	2018	THE NEW ENGLAND JOURNAL OF MEDICINE	239	论著
8	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis	Chaisson, RE	Johns Hopkins Univ	2019	THE NEW ENGLAND JOURNAL OF MEDICINE	196	论著